Clinical Trial Update: Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating etanercept 50 mg once weekly with an as-needed topical agent for moderate-to-severe plaque psoriasis; results and safety data have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Etanercept (etanercept)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2014-05-02